Head and neck cancer emerging strategies: Advances and new challenges

Current Opinion in Oncology

Volumn 21, Issue 3, 2009, Pages 191-193

  Awada, Ahmad ^a   Castro Jr , Gilberto De ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b Instituto de Oncologia Sao Paulo   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CEDIRANIB; CETUXIMAB; CISPLATIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; IXABEPILONE; LAPATINIB; PEMETREXED; TAXANE DERIVATIVE; VANDETANIB;

ANGIOGENESIS; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; DERMATITIS; DRUG MEGADOSE; DYSPHAGIA; EDITORIAL; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CARCINOMA; INTENSITY MODULATED RADIATION THERAPY; LARYNX CARCINOMA; METASTASIS; MUCOSA INFLAMMATION; OROPHARYNX CARCINOMA; PATIENT CARE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; SQUAMOUS CELL CARCINOMA; DISEASE COURSE; HEAD AND NECK TUMOR; PATHOLOGY; PROGNOSIS; RISK FACTOR;

DISEASE PROGRESSION; HEAD AND NECK NEOPLASMS; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 67650351369     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32832a6e05     Document Type: Editorial

References (16)

1. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21:92-98.
2. Pignon JP, le Maítre A, Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys 2007; 69 (Suppl 2):S112-S114.
3. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
4. Hitt R, López-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23:8636-8645.
5. Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705-1715.
6. Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704.
7. Paccagnella A, Buffoli A, Koussis H, et al. Concomitant chemoradiotherapy (CT/RT) vs neoadjuvant chemotherapy with docetaxel/cisplatin/ 5-fluorouracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study. J Clin Oncol 2008; 26:316s.
8. Wendt TG, Grabenbauer GG, Rödel CM, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16:1318-1324.
9. Adelstein DJ, Leblanc M. Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 2006; 24:2624-2628.
10. Vermorken J, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-1127.
11. Seiwert TY, Cohen EE, Wang X, et al. Use of systematic analysis of DNA repair pathways in head and neck cancer to identify XPF as a novel predictor of induction response, and pMK2 relationship to chemoradiotherpy. J Clin Oncol 2008; 26:316s.
12. Hao D, Lau HY, Eliasziw M, et al. A comprehensive evaluation of the prognostic value of ERCC1 protein expression, mRNA and genotype in locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2008; 26:318s.
13. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100:261-269.
14. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008; 26:3128-3137.
15. Burtness BA, Manola J, Axelrod R, et al. A randomized phase II study of ixabepilone (BMS-247550) given daily×5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19:977-983.
16. Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005; 365:1927-1933.